bioAffinity Technologies Inc., a Delaware-based corporation, has entered into an At-The-Market Issuance Sales Agreement with WallachBeth Capital LLC. This agreement allows for the sale of the company's common stock, valued at $0.007 per share, through an "at the market offering" program. Under this arrangement, shares may be sold directly on the Nasdaq Capital Market or other existing trading platforms at prevailing market prices. The company retains control over the sale parameters, including the number of shares, the timing, and any minimum price constraints. The agreement remains in effect until all shares are sold, but can be terminated by either party with a 10-day notice.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。